In ®Entresto we trust

Sacubitril/Valsartan (S/V) is a novel and remarkably effective opportunity to treat heart failure with reduced ejection fraction (HFrEF). However, patients with HFrEF induced by cancer therapy were a priori excluded from the registration study. The value of S/V in this important subgroup of patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Camilli, Massimiliano, Del Buono, Marco Giuseppe, Menna, Pierantonio, Minotti, Giorgio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643399/
https://www.ncbi.nlm.nih.gov/pubmed/33292733
http://dx.doi.org/10.1186/s40959-020-00083-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643399/
https://www.ncbi.nlm.nih.gov/pubmed/33292733
http://dx.doi.org/10.1186/s40959-020-00083-7

Ejemplares similares